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Excessive levels of B cell activating factor (BAFF) are found in patients with active chronic graft-versus-host
disease (cGVHD). In mice, BAFF has been shown to be essential for B cell recovery after myeloablation. To
assess how BAFF levels relate to transplantation factors and subsequent development of cGVHD, we prospec-
tively monitored 412 patients in the ﬁrst year after allogeneic peripheral blood or bone marrow hematopoietic
stem cell transplantation (HSCT) and censored data at time of cGVHD onset. In patients who did not develop
cGVHD, we afﬁrmed a temporal pattern of gradually decreasing BAFF levels as B cell numbers increase after
myeloablative conditioning. In contrast, after reduced-intensity conditioning, BAFF levels remained high
throughout the ﬁrst post-HSCT year, suggesting that the degree of myeloablation resulted in delayed B cell
recovery associated with persistence of higher BAFF levels. Given that high BAFF/B cell ratios have been asso-
ciated with active cGVHD, we examined differences in early BAFF/B cell ratios and found signiﬁcantly different
BAFF/B cell ratios at 3 months post-HSCT only after myeloablative conditioning in patients who subsequently
developed cGVHD. In addition to HSCTconditioning type, the use of sirolimus was signiﬁcantly associatedwith
higher BAFF levels after HSCT, and this also was potentially related to lower B cell numbers. Taken together, our
results are important for interpreting BAFF measurements in cGVHD biomarker studies.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
B cell activating factor (BAFF) is a key regulator of B cell
homeostasis. BAFF support is required for normal B cell pro-
liferation and survival, and the absence of BAFF or BAFF-R
results in profound B lymphopenia [1,2]. In contrast, excess
BAFF has been associated with persistence of autoreactive
B cells and various autoimmune diseases [3]. These homeo-
static functionsof BAFFwere exempliﬁed in a studyof patients
with common variable immunodeﬁciency, in whom soluble
BAFF levels were inversely correlated with peripheral B cell
numbers and the expression of BAFF receptors [4]. The clinical
signiﬁcanceof this cytokinepathway is alsohighlightedby the
recent Food and Drug Administration approval of belimumab,
an anti-BAFF monoclonal antibody for the treatment of sys-
temic lupus erythematosus, in which neutralization of high
BAFF levels leads to a reduction in pathogenic autoantibodies
and clinical improvement of disease [5,6].edgments on page 674.
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14.01.021BAFF also has an important role in the reconstitution of B
cells andnormal B cell functionafter stemcell transplantation.
In murine models, BAFF is required for reconstitution of the
B cell compartment after myeloablation [1]. Soluble BAFF
levels are characteristically high when patients are B-lym-
phopenic, and gradually decrease as thenumber of circulating
B cells returns to normal levels [7-9]. After transplantation,
increasednumbers of bonemarrow (BM)B cell precursors and
early recovery of circulating B cells have been observed in
patientswhodonotdevelopchronic graft-versus-hostdisease
(cGVHD) [10-13].
Alongwith supporting the recovery of normal B cells after
stem cell transplantation, BAFF also has been proposed to
contribute to the development of cGVHD [14,15]. Despite
having signiﬁcantly higher BAFF levels, patients with cGVHD
often have low total numbers of circulating B cells compared
with patients without cGVHD, resulting in relatively high
BAFF/B cell ratios and the presence of circulating activated
B cells. Although the mechanisms by which BAFF contributes
to the development of cGVHD are not well established, many
studies strongly support a role for B cells in this disease.
Whereas the cellular sources of BAFF are unknown in cGVHD,
inducible expression from neutrophils, monocytes/macro-
phages, dendritic cell subsets, T cells, and activated B cells is
known to occur in other inﬂammatory states [16,17].Transplantation.
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B cell recovery by BAFF might inﬂuence the subsequent
development of cGVHD [18]. To examine this issue, we pro-
spectively monitored a large cohort of 412 patients with
serial measurements of BAFF levels and B cell numbers in
the ﬁrst year after allogeneic HSCT before development of
cGVHD. This study identiﬁes several key variables, including
the intensity of pretransplantation conditioning therapy and
sirolimus use, important for interpreting differences in BAFF
levels and B cell numbers in the ﬁrst year after HSCT.
METHODS
Patient Characteristics
Serial blood samples for analysis of BAFF levels and B cell reconstitution
were obtained from 412 patients who had undergone allogeneic HSCT and
survived at least 100 days post-HSCTat the Dana-Farber Cancer Institute and
Brigham and Women’s Hospital between 2000 and 2008. Written informed
consent was obtained in accordance with the Declaration of Helsinki. The
study was approved by the Human Subjects Protection Committee of the
Dana-Farber/Harvard Cancer Center.
Table 1 summarizes clinical characteristics of the patient cohort. Pa-
tients who underwent umbilical cord blood transplantation were excluded
from this analysis, because B cell recovery and BAFF levels have been shown
to be very different in these patients [19,20]. Donors were HLA-matched in
86% of the transplantations, including 42% with related donors. After HSCT,
24% of the patients experienced acute graft-versus-host disease (aGVHD),
and 67% developed cGVHD. cGVHD was categorized according to docu-
mented clinical examination ﬁndings and laboratory test results using bothTable 1
Clinical Characteristics of the Study Population
Characteristic All
Patients, n (%) 412 (100)
Age, median (range) 49 (18-72)
Female sex, n (%) 184 (44.7)
Male recipientefemale donor, n (%) 98 (23.8)
Donor HLA match, n (%)
Matched related 183 (41.5)
Matched unrelated 194 (44)
Mismatched 35 (8.5)
Conditioning regimen, n (%)
MAC 187 (45.4)
RIC 225 (54.6)
Stem cell source, n (%)
Bone marrow 37 (9)
PBSC 375 (91)
Diagnosis, n (%)
Acute myelogenous leukemia 134 (32.5)
CLL/SLL/PLL 46 (11.2)
Chronic myelogenous leukemia 45 (10.9)
Hodgkin disease 24 (5.8)
Multiple myeloma/PCD 8 (1.9)
Anemia/RCD 11 (2.7)
Acute lymphoblastic leukemia 39 (9.5)
Myelodysplastic syndrome 33 (8)
Myeloproliferative disorder 7 (1.7)
Non-Hodgkin lymphoma 65 (15.8)
GVHD prophylaxis, n (%)
Tacrolimus/sirolimus/MTX 161 (39.1)
Tacrolimus/sirolimus, no MTX 93 (22.6)
Tacrolimus/MTX 115 (27.9)
Tacrolimus, no MTX 21 (5.1)
Cyclosporine-containing 13 (3.2)
Sirolimus/mycophenolate mofetil 5 (1.2)
Other 4 (1)
Grade II-IV aGVHD, n (%) 100 (24.3)
CLL indicates chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; PLL
PBSC, peripheral blood stem cells; MTX, methotrexate.
Details of conditioning regimens and GVHD prophylaxis:
MAC: Total body irradiation on days -4 to -2; cyclophosphamide 1800 mg/m2 i.v.
GVHD prophylaxis: MTX 15mg/m2 i.v. on day 1, then 10 mg/m2 i.v. daily on days 3,
RIC: Fludarabine 30 mg/m2 i.v. daily on days -5 to -2; busulfan 0.8 mg/kg i.v. daily on
(day 11 is optional); tacrolimus 0.05mg/kg twice daily starting on day -3 and titrate
on, titrated to level.the Seattle criteria [21] and National Institutes of Health cGVHD consensus
criteria [22]. The median time from HSCT to the development of cGVHDwas
222 days (range, 71 to 994 days). Median follow-up for all surviving patients
was 72months (range, 30 to 133months) after HSCT. Samples obtained after
cGVHD development or after disease relapse were excluded from our
analysis.
Processing of Patient Plasma
Blood was drawn into standard EDTA-containing collection tubes.
Plasma was separated from whole blood cells by centrifugation at 600  g,
stored in aliquots at 80C, and used for BAFF measurements after a ﬁrst or
second thaw.
BAFF ELISA
Soluble BAFF in patient plasma samples was measured with a
commercially available ELISA kit (R&D Systems, Minneapolis, MN) according
to the manufacturer’s recommended procedures.
Flow Cytometry Analysis of Peripheral Blood Cells
Fluorochrome-conjugated monoclonal antibodies speciﬁc for CD3, CD4,
CD19, CD20, CD25, CD27 (BD Biosciences, San Jose, CA), and CD8 (Beckman
Coulter, Fullerton, CA) were used to stain fresh whole blood. After staining,
RBCs were lysed with Pharm Lyse (BD Bisosciences) on an automated TQ-
Prep workstation (Beckman Coulter). Flow cytometry was performed with
a FACSCanto II ﬂow cytometer (BD Biosciences) and analyzed using BD
FACSDiva software, or on a Beckman Coulter FC500 ﬂow cytometer and
analyzed using Beckman Coulter CXP analysis software. We found no dif-
ference in B cell numbers using CD19 or CD20 cell surface staining. B cell
percentage was based on enumeration of cells expressing CD20.No cGVHD cGVHD P Value
137 (33.3) 275 (66.7)
48 (18-72) 50 (18-72) .88
70 (51.1) 114 (41.5) .07
16 (11.7) 82 (29.8) <.001
<.001
80 (51) 103 (36.3)
48 (30.6) 146 (51.4)
9 (6.6) 26 (9.5)
.6
65 (47.4) 122 (44.4)
72 (52.6) 153 (55.6)
.008
21 (15.3) 16 (5.8)
116 (84.7) 259 (94.2)
.004
52 (38) 82 (29.8)
12 (8.8) 34 (12.4)
15 (10.9) 30 (10.9)
4 (2.9) 20 (7.3)
7 (5.1) 1 (0.4)
6 (4.4) 5 (1.8)
15 (10.9) 24 (8.7)
6 (4.4) 27 (9.8)
1 (0.7) 6 (2.2)
19 (13.9) 46 (16.7)
.18
50 (36.5) 111 (40.4)
24 (17.5) 69 (25.1)
47 (34.3) 68 (24.7)
7 (5.1) 14 (5.1)
4 (2.9) 9 (3.3)
2 (1.5) 3 (1.1)
3 (2.2) 1 (0.4)
22 (16.1) 7 (28.4) .007
, prolymphocytic leukemia; PCD, plasma cell diseases; RCD, red cell diseases;
daily on days -6 and -5.
6, and 11; tacrolimus 0.02 mg/kg IVCI starting on day -3 and titrated to level.
days -5 to -2. GVHD prophylaxis: MTX 5 mg/m2 i.v. daily on days 1, 3, and 6
d to level; sirolimus 12mg orally on day -3, then 4mg orally daily from day -2
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Patient baseline and transplantation characteristics were reported
descriptively and comparedusing the Fisher exact test orWilcoxon rank-sum
test. BAFF, B cell, and BAFF/B cell ratio data were analyzed descriptively at
each time point and comparedusing theWilcoxon rank-sum test. All P values
are 2-sided at signiﬁcance level of .05. Multiple comparisons were not
considered. The Kaplan-Meier method was used to estimate overall survival
and progression-free survival. Overall survival was calculated from the date
of transplantation to date of death, and progression-free survival was
calculated from the date of transplantation to time of relapse/disease pro-
gression or death, whichever occurred ﬁrst. Multivariable linear regression
analysis was performed to assess factors that potentially affect elevated BAFF
levels. All calculations were performed using SAS 9.2 (SAS Institute, Cary, NC)
and R 2.10.1 (R Project for Statistical Computing, Vienna, Austria).RESULTS
BAFF Level and B Cell Recovery Are Associated with
Intensity of the Conditioning Regimen and Stem Cell
Source
We examined changes in plasma BAFF levels and recon-
stitution of B cells in the ﬁrst year post-transplantation in
412 adult patients with hematologic malignancies who un-
derwent allogeneic HSCT. This was the ﬁrst allogeneic HSCT
for 96.4% of the patients. Patients received granulocyte
colony stimulating factoremobilized peripheral blood (PB;
91%) or BM (9%) stem cells. The 5-year overall survival and
progression-free survival for the entire cohort wwere 56%
and 47%, respectively. Because subsequent treatment would
affect both circulating B cells and BAFF levels, patients were
censored at the time of cGVHD onset or relapse. None of the
patients developed graft failure. Two-thirds of the patients
(275 of 412; 67%) developed cGVHD at a median of 7.4
months after HSCT (the cGVHD cohort), and 137 patients
(33%) did not develop cGVHD during the follow-up period
(the no cGVHD cohort).
The cGVHD cohort differed from the no cGVHD cohort
in several important variables (Table 1), including signiﬁ-
cantly more male patients with female donors, greater use of
matched unrelated donors (MUD), greater use of mobilized
PB stem cell grafts, and more history of previous grade II-IV
aGVHD. All of these variables have been associated with
increased risk of cGVHD.
We ﬁrst examined whether the intensity of the condi-
tioning regimen inﬂuences B cell reconstitution after HSCT
[23-27].We found that thepatternsof BAFFandB cell recovery
differed in the patients who received myeloablative condi-
tioning (MAC) and those who received reduced-intensity
consitioning (RIC). BAFF levels were signiﬁcantly different in
the 2 groups at 3 months and 12 months post-HSCT. Specif-
ically, median BAFF level was signiﬁcantly higher in the MAC
group at 3 months post-HSCT (10.62 ng/mL [range, 1.65 to
40.47 ng/mL] versus 7.93 ng/mL [range, 0.79 to 61.03 ng/mL];
P¼ .02), but signiﬁcantly higher in the RIC group at 12months
post-HSCT (8.0 ng/mL [range, 2.14 to 20.69 ng/mL] versus 5.48
ng/mL [range, 2.37 to 25.3 ng/mL]; P ¼ .02). These increased
BAFF levels do not appear to be associated with total B cell
numbers, given the lack of signiﬁcant difference in B cell
numbers or BAFF/B cell ratios between the 2 groups at any
time point after HSCT (data not shown).
To determine whether B cell recovery was related to the
level of engraftment with donor cells, we examined the
available total PB cell chimerism data, and found no signiﬁ-
cant correlation between BAFF/B cell and chimerism at
day þ30 or day þ100 post-HSCT (Supplemental Table S1).
Because this potential effect of HSCT conditioning on BAFF
and B cell values affect how these values are interpreted
in cGVHD studies, we further examined the data bystratifying the cohort according to subsequent development
of cGVHD.
BAFF Level and B Cell Recovery Before Development of
cGVHD
To identify differences in B cell recovery before the
development of cGVHD, we censored patients after the onset
of cGVHD, but stratiﬁed them according to cGVHD develop-
ment. First, to further examine the relationship between
B cell number and BAFF levels, we compared BAFF and B cell
recovery separately in patients in the MAC and RIC groups
who either developed cGVHD later or who never developed
cGVHD. Of these 412 patients, 275 (67%) developed cGVHD at
a median of 7.4 months after HSCT (the cGVHD cohort), and
137 patients (33%) did not develop cGVHD during the follow-
up period (the no cGVHD cohort).
BAFF levels and B cell numbers weremeasured at 1, 3, 6, 9,
and 12 months after HSCT in all available samples from both
the MAC and RIC groups. Figure 1 compares the 2 condi-
tioning groups before development of cGVHD. The general
pattern of BAFF and B cell recovery was similar in the no
cGVHD cohort in both groups, but these patterns were
temporally distinct and appeared to reﬂect the level and rate
of B cell recovery. Early after HSCT, BAFF levels were high in
both groups, whereas B cell recovery was slightly slower in
the RIC group. In each group, the decrease in BAFF levels
reﬂected the tempo of recovery of peripheral B cells. This
coordinated pattern of BAFF and B cell number increase is
consistent with previous reports demonstrating a low inci-
dence of cGVHD in patients who experience rapid recovery of
normal B cells. Taken together, and consistent with previous
ﬁndings, these data suggest a relationship between BAFF
level and the degree of B lymphopenia.
We found that patterns of BAFF and B cell recovery
differed in patients who subsequently developed cGVHD.
In patients in the MAC and RIC groups who subsequently
developed cGVHD (Figure 1), BAFF levels remained elevated
and relatively stable, whereas B cell numbers slowly
increased in the ﬁrst year post-HSCT. To ascertain whether
high BAFF level was related to naïve B lymphopenia, we
examined CD27, a marker of antigen-experienced B cells.
CD19þCD27þ B cell percentages were available for only
a small subset of these patients (64 of 412) at various time
points. In this small patient subset, the percentage of
CD19þCD27þ B cells was not signiﬁcantly different in the 2
groups at any time point, indicating that the majority of cells
likely were naive B cells.
Interestingly, the frequency of CD27þ B cells was high at 1
month post-HSCT in both the cGVHD and no cGVHD cohorts
(data not shown), possibly reﬂecting increased proportions
of antigen-experienced B cells or early BM CD27þ B cells
[28,29]. Thus, taken together, our data show that the cGVHD
and no cGVHD cohorts within each PB/BM transplantation
conditioning group experience varying kinetics of BAFF level
change with B cell number increase after HSCT, but with
delayed B cell recovery in those who subsequently develop
cGVHD.
Because high BAFF/B cell ratios in patients with active
cGVHD may be pathobiologically relevant [13,30], we exam-
ined whether a difference in BAFF/B cell ratio was evident
before disease onset. A more detailed analysis of the data for
the cGVHD and no cGVHD cohorts is shown in Figure 2. In the
MAC group, BAFF levels were persistently and signiﬁcantly
higher in the cGVHD cohort compared with the no cGVHD
cohort (Figure 2A) (6 months: 9.79 ng/mL versus 5.71 ng/mL,
Figure 1. BAFF levels and B cell recovery after allogeneic HSCT. Patients who received either MAC or RIC are shown separately according to subsequent development
of cGVHD. (A) BAFF levels (squares) and B cell numbers (triangles) after MAC in patients in the no cGVHD cohort. (B) BAFF levels (squares) and B cell numbers
(triangles) after MAC in patients in the cGVHD cohort. (C) BAFF levels (squares) and B cell numbers (triangles) after RIC in patients in the no cGVHD cohort. (D) BAFF
levels (squares) and B cell numbers (triangles) after RIC in patients in the cGVHD cohort. *Statistically signiﬁcant differences (P < .05). Note that blood samples
obtained after the clinical onset of cGVHD were excluded from the analysis.
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12 months: 8.68 ng/mL versus 4.3 ng/mL, P ¼ .02). Also in
the MAC group, B cell numbers were signiﬁcantly lower at
3months post-HSCT in the cGVHD cohort comparedwith the
no cGVHD cohort (10 cells/uL versus 37 cells/uL; P ¼ .008;
Figure 2C). This corresponded to a higher BAFF/B cell ratio in
the MAC group at this time point (1.11 versus 0.37 in the RIC
group; P ¼ .01; Figure 2E).
The only signiﬁcant difference seen in theRIC groupwas at
6 months, when BAFF levels were signiﬁcantly higher in the
nocGVHDcohort (Figure2B) (9.92ng/mLversus7.09ng/mL in
the cGVHD cohort; P ¼ .05). This peak in BAFF level after RIC
was followed by a more rapid (albeit not statistically signiﬁ-
cant) increase in total B cell numbers at 9 months and 12
months post-HSCT in the no cGVHD cohort compared with
the cGVHD cohort (Figure 2D). Taken together, our data sug-
gest that BAFF levels in the ﬁrst year after transplantation are
affected by the intensity of conditioning. The persistence of
the high BAFF levels associated with the subsequent devel-
opment of cGVHD is most evident after MAC.Effects of aGVHD and Corticosteroid Therapy on BAFF
Level
To examine the role of aGVHD, we compared BAFF levels,
B cell numbers, and BAFF/B cell ratios in patients with cGVHD
and a history of aGVHD and patients with de novo cGVHD,
and found no signiﬁcant differences in any measure at any
time point (data not shown). Because high-dose corticoste-
roid therapy is known to be associated with lower BAFF
levels [31], each patient was further categorized by the use of
prednisone either at any dose or only at doses >30 mg/day
(prednisone or equivalent) at the time of sample collection
for BAFF measurement.A total of 216 patients received prednisone at any dose
in the ﬁrst year after HSCT, and 100 patients received
>30 mg/day. After excluding samples obtained from patients
receiving any dose or only >30 mg/day of prednisone at the
time of sample collection from analysis, we observed a
similar temporal pattern in BAFF levels in the 2 groups as
was seen for all patients. BAFF levels remained signiﬁcantly
higher in the no cGVHD cohort at 1 month post-HSCT
(15.21 ng/mL versus 11.44 ng/mL; P ¼ .004), but decreased
over time, becoming signiﬁcantly lower in this cohort by 12
months post-HSCT (5.57 ng/mL versus 9.57 ng/mL; P ¼ .009;
data not shown). This analysis suggests that steroid treat-
ment did not affect the relative differences in BAFF levels
seen in patients who subsequently developed cGVHD
compared with those who did not develop cGVHD.
Inﬂuence of Clinical Factors and Sirolimus on BAFF and B
Cell Recovery
We attempted to uncover additional factors contributing
to high BAFF levels by examining factors that can potentially
affect BAFF and B cell levels. Importantly, previous treatment
with anti-B cell or antilymphocyte antibody therapy was not
associated with the development of cGVHD development in
our study population. None of our patients received antith-
ympcyte globulin as part of pretransplantation conditioning.
Of the 114 patients with B cell non-Hodgkin lymphoma or
chronic lymphocytic leukemia, 60 received rituximab or
ibritumomab tiuxetan and 6 received alemtuzumab within 6
months before HSCT. Importantly, when we excluded the 60
patients who received B cellespeciﬁc depletion therapy, the
pattern of BAFF levels remained the same, but B cell recovery
was more robust in the cGVHD cohort and less robust in the
no cGVHD cohort, resulting in no between-group differences
in B cell number or BAFF/B cell ratio (data not shown).
Figure 2. Patterns of BAFF levels, B cell numbers, and BAFF/B cell ratios after HSCT before development of cGVHD. Serial values during the ﬁrst year after HSCT for
patients who received either MAC (A, C, and E) or RIC (B, D, and F) before HSCT. Patients who developed cGVHD (triangles) are compared with those who did not
develop cGVHD (squares). *Statistically signiﬁcant difference (P < .05). Median values for those that were signiﬁcantly different after MAC were as follows: 6 months:
cGVHD, 9.79 ng/mL (range, 0.62 to 58.43 ng/mL) versus no cGVHD, 5.71 ng/mL (range, 0.08 to 34.49 ng/mL), P ¼ .025; 9 months: cGVHD, 12.3 ng/mL (range, 1.75 to
37.38 ng/mL) versus no cGVHD, 3.99 ng/mL (range, 0.83 to 31.82 ng/mL), P ¼ .004; 12 months: cGVHD, 8.68 ng/mL (range, 2.37 to 22.17 ng/mL) versus no cGVHD, 4.3
ng/mL (range, 3.48 to 25.3 ng/mL), P ¼ .02. Median values for those that were signiﬁcantly different after RIC are as follows: 6 months: cGVHD, 7.09 ng/mL (range, 0 to
26.01 ng/mL) versus no cGVHD, 9.92 ng/mL (range, 0 to 80.49 ng/mL); P ¼ .05. Signiﬁcant differences in median total B cell numbers were seen at 3 months after MAC:
cGVHD, 10 cells/mL (range, 0 to 631.41 cells/mL) versus no cGVHD, 37 cells/mL (range, 0 to 434.64 cells/mL); P ¼ .008. BAFF/B cell ratios were calculated as described
previously and are depicted on a log scale. A signiﬁcant difference in median values was seen at 3 months after MAC: cGVHD, 1.11 (range, 0.05 to 20.07) versus no
cGVHD, 0.37 (range, 0.03 to 10.75); P ¼ .01.
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of developing cGVHD, but multivariable linear regression
analysis detected no signiﬁcant associations among patient
age, donorerecipient sex mismatch, related or unrelated
graft donor, stem cell source, or BAFF level at any time during
the ﬁrst year post-HSCT (Table 2). B cell recovery was faster
in younger patients than in older patients (median, 143.7
days versus 27.7 days [P ¼ .049] at 9 months and 229.4 days
versus 46 days [P ¼ .004] at 12 months). In multivariable
analysis, older recipient age was associated with a signiﬁ-
cantly lower total B cell number, but only at the 12-month
time point (P ¼ .002). Multivariable linear regression anal-
ysis showed signiﬁcant associatons between conditioningregimen and donor cell source with BAFF levels at 3 months
post-HSCT (P ¼ .02; Table 2).
Multivariable analysis also revealed that sirolimus use
was most signiﬁcantly associated with higher BAFF levels at
6 months post-HSCT (P ¼ .0006; Table 2). Of note, this sig-
niﬁcant increase in BAFF levels was preceded at the 3-month
time point by a signiﬁcant decrease in B cell numbers
(P ¼ .0005; Table 2). As shown in Figure 3A, BAFF levels
remained high at all times in patients receiving sirolimus
and decreased after MAC as B cell number increased, and,
notably, did not decrease as B cell numbers recovered in
recipients of sirolimus, suggesting that factors other than
total B cell number affect BAFF level. In contrast, B cell
Table 2
Multivariable Linear Regression Models on log (BAFF) and log10 (B cell) at 1, 3, 6, 9, and 12 mo after HSCT
P Value
Log (BAFF) Log10 (B Cell)
Factor 1 3 6 9 12 1 3 6 9 12
Older age versus younger age* .69 .62 .69 .25 .43 .55 .50 .90 .13 .002
Male recipient/female donor versus other .41 .36 .08 .10 .23 .64 .54 .99 .85 .54
PB versus BM stem cell source .62 .02 .91 .47 .32 .54 .24 .61 .60 .76
Matched related donor versus matched unrelated/mismatched donor .73 .12 .70 .49 .11 .54 .89 .75 .66 .69
Sirolimus versus other .97 .054 .0006 .07 .02 .11 .0005 .14 .37 .32
MAC versus RIC .20 .02 .15 .36 .87 .41 .40 .26 .10 .51
* Older is deﬁned as age 50 y in patients receiving MAC and age 60 y in those receiving RIC.
Bold indicates signiﬁcant P values.
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receive sirolimus, and this was associated with gradually
decreasing BAFF levels in these patients (Figure 3B).
Of note, GVHD prophylaxis was typically discontinued
by 6 months post-HSCT in patients exhibiting no signs of
cGVHD. Owing to the relatively small number of patients
who did not receive sirolimus as GVHD prophylaxis in this
study, we were not able to further analyze the effect of
sirolimus in the cGVHD and no cGVHD cohorts.DISCUSSION
cGVHD results from a complex series of immune in-
teractions that occur as the donor immune system develops
in antigenically disparate hosts and recipients. Patients with
cGVHD frequently produce autoantibodies as well as allo-
antibodies, suggesting that the pathogenesis of this disease
reﬂects a critical breakdown in peripheral B cell tolerance.
After allogeneic HSCT, the reestablishment of B cell homeo-
stasis without alloimmunity or autoimmunity may reﬂect
an improved capacity for B cell recovery early after HSCT [10].
This is similar to what has been demonstrated in mouse
models of autoimmunity, where the reconstitution of pe-
ripheral naïve B cells is critical for maintaining B cell toler-
ance. Consequently, the amount of available soluble BAFF
is potentially a pivotal determinant of B cell homeostasis
after HSCT [32,33]. Thus, although preemptive treatment of
cGVHD likely will affect patient outcomes, abrogation of
BAFF in the early post-transplantation period might not be
beneﬁcial. Although BAFF has been implicated in cGVHD,
whether factors in the early post-transplantation period
affect patterns of BAFF levels merits further examination,
because this information affects interpretation of BAFF levels
in ongoing GVHD biomarker studies.Figure 3. Changes in BAFF levels and B cell recovery in patients receiving sirolimus fo
are compared with B cell numbers (right y-axis, triangles) in patients at 1, 3, 6, 9, and 1
(B) Patients who did not receive sirolimus after HSCT. Note: All patients studied afteThis prospective study of 412 patients reveals the dy-
namic interaction between BAFF and B cell reconstitution
and the relationship of this interaction to cGVHD. Patients
were analyzed serially for up to 1 year before the onset of
cGVHD to examine the relationship between BAFF level and
BAFF/B cell ratio and the subsequent development of cGVHD.
Whereas induction of lymphopenia after HSCT was generally
associated with increased BAFF levels, higher BAFF levels
tended to precede more rapid B cell reconstitution, an effect
particularly evident in patients who never developed cGVHD
after RIC (Figure 2B and D). This ﬁnding is consistent with
previous studies demonstrating increased numbers of pre-
cursor B cells early after HSCT in patients who did not
develop cGVHD [10,34]. After more rapid B cell recovery and
a concurrent decline in BAFF levels, patients who did not
develop cGVHD had a signiﬁcantly lower BAFF/B cell ratio at
12 months post-HSCT. This ﬁnding suggests that once B cells
recover and normal B cell homeostasis is established, BAFF
levels become limiting. The decreased amount of BAFF
available per B cell (the BAFF/B cell ratio) potentially pro-
motes B cell tolerance, with preferential survival of non-
alloreactive B cells, which are less likely to contribute to
cGVHD [32,33,35]. Taken together, these results suggest that
preemptive treatment of cGVHD directed at BAFF in the early
post-transplantation period might not be beneﬁcial. In
contrast, prophylactic rituximab therapy also will delay B cell
reconstitution, but will result in high BAFF levels and allow
for a “reset” of BAFF and B cell kinetics that protects against
cGVHD. Although no patients in our study population
received prophylactive rituximab, the increased numbers of
B cells and decreased BAFF/B cell ratio reported in patients
who received prophylactic rituximab and did not develop
cGVHD supports this idea [36].r GVHD prophylaxis after HSCT. Serial median BAFF levels (left y-axis, squares)
2 months post-transplantation. (A) Patients who received sirolimus after HSCT.
r HSCT and before cGVHD onset were combined in this analysis.
C.A. Jacobson et al. / Biol Blood Marrow Transplant 20 (2014) 668e675674In the present study, the large number of HSCT recipients
allowed us to investigate the impact of various HSCT-related
factors on BAFF levels and B cell recovery and the subsequent
development of cGVHD. We found that pretransplantation
conditioning (MAC versus RIC) had a signiﬁcant effect on
the kinetics of BAFF levels and B cell numbers after HSCT.
Older age of HSCT recipients was signiﬁcantly associated
with decreased B cell numbers at 12 months post-HSCT.
An unexpected ﬁnding was the highly signiﬁcant effect of
sirolimus use on BAFF level and B cell reconstitution. Overall,
64% of the patients in this study received sirolimus as part of
GVHD prophylaxis, and receipt of sirolimus was associated
with persistently high BAFF levels, as well as delayed B cell
reconstitution. Although not statistically signiﬁcant, and not
reported in a previous study at our center [37], in the recently
presented Clinical Trials Network study [38], patients
receiving a sirolimus-containing GVHD prophylaxis regimen
exhibited a higher incidence of cGVHD compared with those
patients who did not receive sirolimus (67% versus 59%;
P ¼ .10). Our analysis did not allow us to decipher the
mechanisms responsible for the elevated BAFF levels asso-
ciated with sirolimus administration. The higher BAFF levels
that were associated with the development of cGVHD in
patients who received sirolimus might have been indepen-
dent of sirolimus use. Because sirolimus was associated with
signiﬁcantly lower B cell numbers before the signiﬁcant in-
crease in BAFF levels was seen, it is tempting to speculate
that sirolimus itself may result in higher BAFF levels owing to
induction of B lymphopenia. This idea is plausible, given that
sirolimus is known to hinder B cell development inmice [39].
Previous studies have suggested that inhibition of mamma-
lian target of rapamycin also may contribute to increased
BAFF production [40] or elimination of activated B cells
[41,42].
Taken together, our data reveal the effects of HSCT con-
ditioning, age, and sirolimus on B cell recovery kinetics and
BAFF levels after HSCT. Understanding the potential role of
early high BAFF levels in relation to B cell reconstitution and
attainment of B cell tolerance versus whether high BAFF re-
lates to the promotion of autoreactive B cells will be critical
to an improved understanding of cGVHD pathophysiology.
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